2024-520105-39-00RecruitingPhase 1
A dosimetry trial of uPAR targeted radioligand therapy in patients with glioblastoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Sept 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 17 Jun 2025
- Start date
- 30 Sept 2026
- Lead sponsor
- Curasight A/S
- Diseases
- Glioblastoma
- EU CT number
- 2024-520105-39-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 10
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rigshospitalet Coordinator of this site? Confirm its status | Copenhagen Oe | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.